Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes

NCT04171700 is registered in ClinicalTrials.gov with pharmaand GmbH as lead sponsor.

NCT NCT04171700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04171700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
Lead sponsor
pharmaand GmbH
Phase
Phase 2
Overall status
Terminated
Start date
January 16, 2020
Completion date
July 15, 2022
Enrollment
83 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor